Vertex Pharmaceuticals price target lowered to $441 from $506 at Bernstein
Bernstein lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $441 from $506 and keeps a Market Perform ...
US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and ...
Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results
Key Takeaways Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to ...
Vertex's painkiller results match placebo in study, shares tumble
Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed ...
Cramer’s Mad Dash: Vertex Pharmaceuticals
CNBC’s Jim Cramer delivers his daily Mad Dash. Georgia appeals court removes Fani Willis from Trump 2020 election case ...
The Boston Globe2d
Vertex stock plummets as study results show non-opioid pain drug no better than placebo
Vertex Pharmaceuticals Inc.’s nonaddictive drug for lower back pain didn’t do better than a placebo in a midstage trial, ...
Business Insider1d
Vertex Pharmaceuticals price target lowered to $418 from $509 at Barclays
Barclays lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $418 from $509 and keeps an Equal Weight rating on the shares. The firm says the Phase 2 painful lumbosacral radiculopathy ...
Here’s Why Vertex Pharmaceuticals Incorporated (VRTX) Slid in Q3
Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity” third ...
BioPharma Dive1d
Vertex ‘ends the year in pain’ as latest non-opioid drug data disappoint
Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...
Business Insider1d
Vertex Pharmaceuticals: Buy Rating Despite LSR Trial Setback, Future Prospects Remain Strong
In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $555.00. Discover top-rated stocks from ...
STAT1d
Vertex touts pain drug results, but medicine does not outperform placebo in sciatica study
A Vertex drug hit its mark in a Phase 2 study in chronic pain, but faces questions about its performance versus placebo.
Vertex’s non-opioid drug succeeds in back pain trial
Vertex Pharmaceuticals' suzetrigine shows promising results in treating painful lumbosacral radiculopathy, but stock falls ...